HemoGenix, Inc

09/03/2026

08/06/2026

Bridging In Vitro and In Vivo: Extending the Value of Preclinical Research: https://conta.cc/4tOkiOI

07/21/2026

Immunotoxicity and Immune Cell Testing

HemoGenix® has developed several proprietary assays for in vitro immunotoxicity high-throughput screening and testing as well as other immune assays involving T- and B-lymphocytes and subsets.

Learn more: https://conta.cc/4wNkKh9

06/24/2026

Advancing Drug Development Through Predictive In Vitro Testing

https://conta.cc/4w3pwXL

05/27/2026

In Vitro Preclinical Contract Services

HemoGenix® has been instrumental in promoting in vitro toxicity and safety testing to help our world-wide partners in preclinical drug and safety evaluations. Many of our studies have been included in numerous IND applications. Here are some of our areas of expertise that may be of interest to you:

> Hematotoxicity
> Immunotoxicity
> Mesenchymal Cell Toxicity
> Hepatotoxicity
> Cardiotoxicity
> Renal Toxicity
> Neurotoxicity
> Intestinal Toxicity
> Tumor Cells
> Cell Line Toxicity
> Nanoparticle Toxicity
> ComparaTox™
> High Throughput Screening
> Drug Interaction & Combination
> Mechanism of Action
> Cellular Therapeutics
> Stem Cell Toxicity & Biology
> Cell-Based Assay Services

More information available here: https://conta.cc/4nStxv7

05/12/2026

High-Throughput Toxicity Screening: https://conta.cc/422ZUgH

04/16/2026

HALO®-Tox HT

In Vitro High-Throughput Stem and Progenitor Cell Hematotoxicity Screening and Testing

Learn more: https://conta.cc/4dS4J3y

03/04/2026

Bridging In Vitro and In Vivo: Extending the Value of Preclinical Research

Hematotoxicity testing is a well-established field, and HALO-Tox HT has demonstrated strong in vitro to in vivo concordance, as reported by Olaharski et al. (2009) in Toxicology Letters. Designed in line with the 3Rs, it provides accurate lympho-hematotoxicity data from early discovery through clinical development.


While HemoGenix® does not perform animal studies in-house, we collaborate with CROs to maximize the value of preclinical research.

Learn more: https://conta.cc/4aNJPAC